News | April 28, 2022
Sanofi continues to deliver strong business
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Subscribe To Our Newsletter & Stay Updated
